Littler on course for historic clean sweep in darts season
World No 1 Luke Littler has won every major in 2026 so far and is positioned to achieve a rare clean sweep of titles this year.
Media
Read Full News
Why Investors Are Returning to Bonds as the 10-Year Faces a Century-Long Strain
Despite the 10-year Treasury’s worst run in a century, rising yields are drawing fresh investment into bonds as attractive income options.
Texting for Answers: How an AI Chatbot Is Reaching Pregnant People in Kenya
A text-based AI chatbot in Kenya provides pregnancy and newborn advice, aiming to fill information gaps where search engines and clinics are hard to reach.
Collectors Flock to Stores as Pokémon Turns 30, Target Sees Anniversary Cards Sell Out
Mizuho analysts observed long lines and sellouts at Target over Pokémon’s 30th-anniversary card set, underlining sustained collector demand.
Lawsuit Challenges NIH Practice of Screening Grant Applications for Banned Terms
Researchers sue NIH, alleging First Amendment violations after searches of grant applications for specific terms; case could reshape federal research funding reviews.
News Helicopter Crashes into Flames Near LA Bus Collision, At Least Three Dead
A news helicopter crashed and burst into flames near a bus collision in Los Angeles, killing at least three people. Authorities have released few details.
When an 87-Year-Old’s Offer to Pay for Grandchildren’s Education Fuels Sibling Tension
An adult child questions fairness as an 87-year-old mother wants to fund her grandchildren’s schooling after years of shared support.
Final-day duel at Doncaster: Touleen vs Forty Years On
Touleen and Forty Years On meet on the final day of the St Leger Festival at Doncaster in a key clash that will shape the meeting’s finale.
Celine Dion’s Return: Sold-Out Paris Residency Marks Stage Comeback
Celine Dion reopened her 16-show residency at the Plenitude Arena in Paris, marking her stage return after a lengthy health absence.
AstraZeneca’s Camizestrant Falls Short in Key First‑Line Breast Cancer Trial
AstraZeneca reports camizestrant did not beat standard therapy in SERENA-4 first-line trial, limiting its broader use beyond an existing U.S. approval.